SBC Medical Group Shifts Focus to Asia, Exits US Clinic Operations

TL;DR

**SBC's strategic Asian pivot is overshadowed by critical internal control failures, making it a high-risk bet despite potential growth.**

AI Summary

SBC Medical Group Holdings Inc. (SBC) reported a significant business transformation in its 2025 fiscal year, transitioning from a SPAC to a management company for aesthetic clinics. The company now provides comprehensive management services to 237 franchisee treatment centers in Japan, including 5 independently operated clinics, as of December 31, 2025. Additionally, SBC operates 21 treatment centers in Singapore through its newly acquired Aesthetic Healthcare Holdings (AHH) in November 2024, and one treatment center in Ho Chi Minh City, Vietnam. The company exited the U.S. market by permanently closing its Irvine, California clinic in May 2025, but maintains a strategic minority equity investment in OT Midco, which indirectly holds the OrangeTwist business operating 24 U.S. treatment centers. A critical risk highlighted is the ineffectiveness of disclosure controls and procedures as of December 31, 2025, due to un-remediated material weaknesses in internal control over financial reporting, posing a risk to timely and accurate financial reporting and fraud prevention.

Why It Matters

SBC's strategic pivot to focus on the Asian aesthetic clinic market, particularly Japan and Singapore, while exiting direct U.S. operations, signals a clear geographic and operational strategy for investors. This move could streamline operations and leverage established market presence in Asia, potentially improving profitability and competitive positioning against local players. However, the disclosed material weaknesses in internal controls as of December 31, 2025, are a significant red flag for investors, indicating potential financial reporting inaccuracies and operational inefficiencies that could erode trust and market value. Employees and customers in the U.S. are directly impacted by the closure of the Irvine clinic, while those in Asia may see increased investment and expansion.

Risk Assessment

Risk Level: high — The risk level is high due to the explicit disclosure that "Our disclosure controls and procedures were not effective as of December 31, 2025, as a result of material weaknesses in our internal control over financial reporting that had not been fully remediated as of that date." This directly impacts the reliability of financial reporting and increases the risk of fraud or errors, which is a severe concern for investors.

Analyst Insight

Investors should exercise extreme caution and thoroughly scrutinize SBC's future filings for remediation of the disclosed material weaknesses. Await clear evidence of improved internal controls before considering any significant investment, as current financial reporting reliability is compromised.

Key Numbers

• $48.2 million — aggregate market value of common equity held by non-affiliates (as of June 30, 2025, based on a closing price of $4.64)
• 102,576,943 — shares of Common Stock outstanding (as of February 28, 2026)
• 237 — franchisee treatment centers (in Japan as of December 31, 2025)
• 21 — treatment centers (operated in Singapore through AHH as of December 31, 2025)
• 1 — treatment center (owned and operated in Ho Chi Minh City, Vietnam as of December 31, 2025)
• 24 — treatment centers (operated by OrangeTwist across the United States)
• 2025-12-31 — fiscal year end (date of ineffective disclosure controls)
• 2024-09-17 — Business Combination closing date (Pono changed name to SBC Medical Group Holdings Incorporated)

Key Players & Entities

• SBC Medical Group Holdings Incorporated (company) — registrant
• Pono Capital Two, Inc. (company) — predecessor SPAC
• Aesthetic Healthcare Holdings (company) — acquired subsidiary in Singapore
• OT Midco (company) — strategic minority equity investment
• Yoshiyuki Aikawa (person) — Seller Representative of Legacy SBC
• Nasdaq Stock Market LLC (regulator) — exchange for SBC common stock and warrants
• SEC (regulator) — filing oversight
• Medical Corporation Shobikai (company) — incorporated by Dr. Aikawa in 2004

FAQ

Risk Factors

• Ineffective Disclosure Controls and Procedures [high — operational]: The company reported ineffective disclosure controls and procedures as of December 31, 2025, due to un-remediated material weaknesses in internal control over financial reporting. This poses a significant risk to the timely and accurate reporting of financial information and the prevention of fraud.
• Dependence on Franchisees and Acquired Businesses [medium — market]: SBC's business model relies heavily on its network of 237 franchisee treatment centers in Japan and the performance of its acquired Singaporean operations (AHH) and Vietnamese clinic. Any disruption or underperformance in these centers could materially impact the company's revenue and profitability.
• Competition in Aesthetic Healthcare Market [medium — market]: The aesthetic healthcare market is highly competitive, with numerous established players and new entrants. SBC faces competition from other clinic networks, independent practitioners, and potentially larger healthcare providers expanding into this segment, both in Japan, Singapore, Vietnam, and indirectly in the U.S. through its investment in OrangeTwist.
• Integration of Acquired Businesses [medium — operational]: The acquisition of Aesthetic Healthcare Holdings (AHH) in November 2024 introduces integration risks. Successfully integrating AHH's operations, systems, and culture into SBC's management structure is crucial for realizing the expected synergies and avoiding operational disruptions.
• Reliance on Minority Investment in U.S. Market [low — financial]: While SBC exited its direct U.S. operations, it maintains a strategic minority equity investment in OT Midco, which operates the OrangeTwist business. The financial performance and strategic direction of OrangeTwist are outside of SBC's full control, creating an indirect financial risk.

Industry Context

The aesthetic healthcare market is characterized by growing consumer demand for non-invasive and minimally invasive cosmetic procedures, driven by social media influence and increased disposable income. Competition is intense, with a mix of specialized clinics, medical spas, and dermatology practices. Technological advancements in treatments and a focus on patient experience are key differentiators.

Regulatory Implications

As a company operating in the healthcare sector across multiple international jurisdictions, SBC is subject to various healthcare regulations, licensing requirements, and data privacy laws (e.g., HIPAA in the U.S. context for its investment, and similar regulations in Japan, Singapore, and Vietnam). Non-compliance can lead to significant fines and operational disruptions.

What Investors Should Do

1. Monitor remediation of internal control weaknesses.
2. Evaluate performance of international operations.
3. Assess the strategic value of the OrangeTwist investment.

Key Dates

• 2024-11-01: Acquisition of Aesthetic Healthcare Holdings (AHH) — Significantly expanded SBC's international presence, adding 21 treatment centers in Singapore.
• 2025-05-01: Permanent closure of Irvine, California clinic — Marked SBC's exit from direct U.S. operations, shifting focus to its management company model.
• 2025-12-31: Fiscal year end and date of ineffective disclosure controls — Indicates ongoing material weaknesses in internal controls, posing a risk to financial reporting accuracy.
• 2024-09-17: Business Combination closing date (Pono name change to SBC Medical Group Holdings Incorporated) — Formalized the company's transition and new corporate identity as a management company for aesthetic clinics.

Glossary

SPAC

Special Purpose Acquisition Company. A shell company that is created to raise capital through an initial public offering (IPO) for the purpose of acquiring an existing company. (SBC transitioned from being a SPAC to its current operational structure, indicating a significant business transformation.)

Material Weaknesses

A deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company's annual or interim financial statements will not be prevented or detected on a timely basis. (The presence of un-remediated material weaknesses directly impacts the reliability of SBC's financial reporting.)

Disclosure Controls and Procedures

Processes designed to ensure that information required to be disclosed in reports filed under the Securities Exchange Act of 1934 is recorded, processed, summarized, and disclosed within the time periods specified by the SEC. (The ineffectiveness of these controls, as reported by SBC, raises concerns about the accuracy and timeliness of public disclosures.)

Franchisee

An individual or entity granted the right to engage in a business or to offer, sell, or distribute goods or services under a marketing plan or system prescribed by the franchisor. (SBC's primary business model involves providing management services to a large network of 237 franchisee treatment centers in Japan.)

Year-Over-Year Comparison

The company has undergone a significant business transformation, shifting from a SPAC to a management company for aesthetic clinics. This fiscal year marks the operationalization of this new model, with a substantial network of 237 franchisee centers in Japan and expanded international presence through the acquisition of AHH in Singapore. A key negative development compared to previous periods is the identification and ongoing un-remediated material weaknesses in internal control over financial reporting, leading to ineffective disclosure controls.

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SBC The Nasdaq
• $11.50 — of Common Stock at an exercise price of $11.50 per share SBCWW The Nasdaq Stock Ma
• $4.64 — date on the Nasdaq Stock Market LLC of $4.64. The number of shares of registrant's
• $10.00 — s (the "Placement Units") at a price of $10.00 per Placement Unit in a private placeme
• $7.8 million — business, for cash consideration of SGD$7.8 million (equivalent to approximately US$5.8 mil
• $5.8 million — million (equivalent to approximately US$5.8 million). As a result of this acquisition, we o
• $14.2 million — ion of JPY 2,040 million (approximately $14.2 million). In the same month, we appointed Dr. S
• $20 million — ates, for a total cash consideration of $20 million. In addition, we committed to make an a
• $5.0 million — make an additional cash contribution of $5.0 million in December 2026 for newly issued commo

Filing Documents

• sbc-20251231.htm (10-K) — 7081KB
• sbc-ex3_1.htm (EX-3.1) — 124KB
• sbc-ex3_2.htm (EX-3.2) — 18KB
• sbc-ex4_5.htm (EX-4.5) — 56KB
• sbc-ex19_1.htm (EX-19.1) — 75KB
• sbc-ex21_1.htm (EX-21.1) — 39KB
• sbc-ex23_1.htm (EX-23.1) — 6KB
• sbc-ex31_1.htm (EX-31.1) — 16KB
• sbc-ex31_2.htm (EX-31.2) — 16KB
• sbc-ex32_1.htm (EX-32.1) — 9KB
• sbc-ex32_2.htm (EX-32.2) — 10KB
• 0001193125-26-127557.txt ( ) — 23636KB
• sbc-20251231.xsd (EX-101.SCH) — 2269KB
• sbc-20251231_htm.xml (XML) — 4889KB

Risk Factors

Risk Factors 74 Item 1B. Unresolved Staff Comments. 103 Item 1C. Cybersecurity . 103 Item 2. Properties . 104 Item 3. Legal Proceedings. 104 Item 4. Mine Safety Disclosures. 104 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. 105 Item 6. [Reserved]. 105 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 106 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk. 117 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data. F- 1 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure. 116 Item 9A.

Controls and Procedures

Controls and Procedures. 116 Item 9B. Other Information. 118 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. 118 PART III Item 10. Directors, Executive Officers and Corporate Governance. 119 Item 11.

Executive Compensation

Executive Compensation. 119 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. 119 Item 13. Certain Relationships and Related Transactions, and Director Independence. 119 Item 14. Principal Accountant Fees and Services. 119 PART IV Item 15. Exhibits and Financial Statement Schedules 120 Item 16. Form 10-K Summary 122 Table of Contents P ART I

B usiness

Item 1. B usiness. Unless the context indicates otherwise, any references herein to the "Company", "we", "us" and "our" refer to (i) SBC Medical Group, Inc. (formerly known as SBC Medical Group Holdings Incorporated), a Delaware corporation ("Legacy SBC"), and its consolidated subsidiaries and variable interest entity ("VIE"), prior to the consummation of the Business Combination and to (ii) SBC Medical Group Holdings Incorporated, the Combined Entity and its consolidated subsidiaries and VIE following the Business Combination, and reference herein to "Pono" refers to Pono Capital Two, Inc., the predecessor company prior to the consummation of the Business Combination. Company Overview History We were originally incorporated in Delaware on March 11, 2022 under the name "Pono Capital Two, Inc.," referred to herein as "Pono," as a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. On August 9, 2022, Pono consummated its IPO of 11,500,000 units (the "Units" and, with respect to the Class A common stock included in the Units being offered, the "Public Shares" and with respect to the warrants included in the Units, the "Public Warrants") (the "Pono IPO"). Simultaneously with the consummation of the closing of the Pono IPO, Pono consummated the private placement of an aggregate of 634,375 units (the "Placement Units") at a price of $10.00 per Placement Unit in a private placement to the Sponsor (the "Private Placement"). On September 26, 2022, the Class A common stock and Public Warrant included in the Units began separate trading on The Nasdaq Global Market under the symbols "PTWO" and "PTWOW," respectively. On January 31, 2023, Pono entered into an Agreement and Plan of Merger (as subsequently amended from time to time, the "Merger Agreement") with Pono Two Merger Sub, Inc., a Delaware corpo

View Full Filing

View this 10-K filing on SEC EDGAR